GS Next week $REGN $MRK hosting #ASCO20 events. For REGN focus will be on Libtayo &amp;company’s bispecific platform, while for MRK incremental Keytruda data (TNBC, HCC&amp;MSI-high), but more of debate is around evolving competitive landscape in front-line lung given Roche’s TIGIT data.